

Discovery metabolomics and lipidomics at unmatched scale.

Sapient is a biomarker discovery organization providing bespoke discovery metabolomics and lipidomics services to accelerate drug development programs.

Leveraging high throughput mass spectrometry, biocomputational analysis, and large-scale human biology datasets, we can rapidly identify, validate, and translate dynamic small molecule biomarkers of health, disease, and drug response.

High-Throughput Profiling

with next-gen analytical technologies

Sapient's proprietary rapid LC-MS (rLC-MS) systems allow us to take a biological sample like blood and, in that sample, capture and measure thousands of small molecules.



>15,000 small molecule biomarkers assayed per biosample in nontargeted method



Profiles broad, complex chemistries

including polar metabolites, polar lipids, nonpolar lipids, and bioactive lipids



Up to 1,400 metabolites identified

in large-scale studies and >13K reference standards for putative structural insights for unknown molecules



Diverse sample types

including plasma / serum, tissue, CSF, urine, breast milk, dried blood spots, and many others




<1 minute

analytical cycle time



Capacity to analyze

>5,000 biosamples per day



Why small molecules?

Circulating chemistry is key to understanding the non-genetic factors that influence disease. Dynamic organ physiology, inter-organ communication, host-disease interactions, and host-environment exposures are encoded in small molecule biomarkers.

Sapient focuses on small molecules because they have the potential to provide an unprecedented view into host <u>and</u> disease factors that modulate health status, disease pathobiology, and drug response across individuals.

Biocomputational Analysis to rapidly derive actionable insights

Our expert data science team **applies Al and machine learning approaches** to analyze and integrate the large-scale datasets we generate to identify key small molecule biomarkers of interest.



Multi-scale analyses & models

distilling tens of thousands of small molecule measures down to pathways and biomarkers

Mapping biomarker associations across time, diseases, treatments, and more

Biomarker V. Drug Cytokine Associations COCCET B.-2 CO

DynamiQ[™] Insights Engine to validate biomarker discoveries

Sapient has built an expansive in-house biorepository of serial samples in which we have collected metabolite, lipid, protein, cytokine, and other omics measures – offering a deeply phenotyped database for longitudinal analysis.

We use this data to confirm your biomarker findings in independent populations and further explore associations.



 $\hbox{Multi-omics measures integrated from}$

62,000+ human biosamples



4 - 10 years of follow-up

across individuals, with real-world data on:

- Adjudicated clinical outcomes
- Demographic features
- Lifestyle factors
- Response to intervention
- Human genetics, microbiome, etc.



68M+ phenotypic data points

linked to spectral data from biosamples



Rapidly growing database

with data for 60+ diseases and disorders and new biosamples added every month



Sapient's multi-omics database and biorepository

Enabling guided analyses for:

- Target identification
- Biomarker discovery
- Biomarker validation
- Patient stratification
- PK/PD metrics
- Predictive response
- Companion diagnostics

Ready to discover more?

Schedule a time to discuss your programs.

sapient.bio discover@sapient.bio 858.290.7010